Access to anti-retroviral drugs, female in Mexico

Mexico: Access to anti-retroviral drugs, female was 58.0% in 2024. ▲ Rising

Latest (2024)
58.0%
Change on year
up 5.5%
World rank
105th
of 141 countries
All-time high
62.0%
in 2021
All-time low
9.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Mexico, 2000–2024

02040602000201220242000: 9 %2001: 11 %2002: 13 %2003: 17 %2004: 18 %2005: 20 %2006: 23 %2007: 25 %2008: 27 %2009: 29 %2010: 30 %2011: 31 %2012: 44 %2013: 43 %2014: 43 %2015: 48 %2016: 49 %2017: 50 %2018: 52 %2019: 56 %2020: 59 %2021: 62 %2022: 59 %2023: 55 %2024: 58 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Mexico stood at 58.0%.

Compared with earlier readings it is up 5.5% on the previous year and up 34.9% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Mexico peaked at 62.0% in 2021 and was at its lowest, 9.0%, in 2000.

Mexico ranks 105th of 141 countries on this measure, in the middle of the range.

The long-run direction has been consistently rising across the 25 years of available data.

Access to anti-retroviral drugs, female in Mexico, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Mexico, 2000 to 2024.
Year % Change
2000 9.0%
2001 11.0% +22.2%
2002 13.0% +18.2%
2003 17.0% +30.8%
2004 18.0% +5.9%
2005 20.0% +11.1%
2006 23.0% +15.0%
2007 25.0% +8.7%
2008 27.0% +8.0%
2009 29.0% +7.4%
2010 30.0% +3.4%
2011 31.0% +3.3%
2012 44.0% +41.9%
2013 43.0% -2.3%
2014 43.0% +0.0%
2015 48.0% +11.6%
2016 49.0% +2.1%
2017 50.0% +2.0%
2018 52.0% +4.0%
2019 56.0% +7.7%
2020 59.0% +5.4%
2021 62.0% +5.1%
2022 59.0% -4.8%
2023 55.0% -6.8%
2024 58.0% +5.5%

Averages by decade

DecadeAverage LowestHighest Years
2000s 19.2% 9.0% 29.0% 10
2010s 44.6% 30.0% 56.0% 10
2020s 58.6% 55.0% 62.0% 5

Countries ranked near Mexico

  1. 103 Kazakhstan 60.0% compare
  2. 103 Kyrgyzstan 60.0% compare
  3. 105 Bulgaria 58.0% compare
  4. 105 Kuwait 58.0% compare
  5. 108 Greece 57.0% compare
  6. 108 Timor-Leste 57.0% compare

See the full ranking of 160 places →

More gender data for Mexico

All data for Mexico →

Frequently asked questions

What is access to anti-retroviral drugs, female in Mexico?
Access to anti-retroviral drugs, female in Mexico was 58.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Mexico?
The highest recorded value was 62.0% in 2021.
What is the lowest access to anti-retroviral drugs, female recorded in Mexico?
The lowest recorded value was 9.0% in 2000.
How does Mexico rank for access to anti-retroviral drugs, female?
Mexico ranks 105th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Mexico?
Over the last ten years it is up 34.9%. The long-run trend across the full record is rising.
Where does this Mexico data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Mexico. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/mexico/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/mexico/">Access to anti-retroviral drugs, female in Mexico</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.